Brief: PAION U.S. License Agreement For BYFAVOTM Between Paion And Cosmo
July 15 (Reuters) - PAION AG PA8G.DE :
* U.S. LICENSE AGREEMENT FOR BYFAVOTM (REMIMAZOLAM) BETWEEN
PAION
AND COSMO ASSIGNED FROM COSMO TO ACACIA
* PAION AG - TERMS OF LICENSE AGREEMENT REMAIN UNCHANGED BUT
WILL
NOW BE BETWEEN PAION AND ACACIA, WITH COSMO NO LONGER BEING A
PARTY TO AGREEMENT.
Source text for Eikon: ID:nEQbLjjLGa
Further company coverage: PA8G.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022